{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:22:16Z","timestamp":1772752936698,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ygyno.2010.08.008","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T10:23:33Z","timestamp":1284719013000},"page":"451-456","source":"Crossref","is-referenced-by-count":49,"title":["Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment"],"prefix":"10.1016","volume":"119","clinical-trial-number":[{"clinical-trial-number":"nct00059787","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00263822","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stephanie V.","family":"Blank","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Christos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn D.","family":"Runowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Liebes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco M.","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.08.008_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0015","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/cncr.23957","article-title":"Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer","volume":"113","author":"Wethington","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0020","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/cncr.23425","article-title":"Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0025","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/modpathol.3800575","article-title":"Epithelial growth factor receptor status in primary and recurrent ovarian cancer","volume":"19","author":"Stadlmann","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0035","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1158\/1078-0432.CCR-05-1436","article-title":"Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer","volume":"11","author":"Psyrri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0040","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","article-title":"Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0045","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2165\/00003495-200666150-00011","article-title":"Panitumumab: in the treatment of metastatic colorectal cancer","volume":"66","author":"Hoy","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14656566.7.2.177","article-title":"A review of erlotinib and its clinical use","volume":"7","author":"Tang","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0055","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2165\/00003495-200464210-00008","article-title":"Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer","volume":"64","author":"Frampton","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0060","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-04-0993","article-title":"Enhanced sensitivity to the HER1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines","volume":"11","author":"Dai","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0065","first-page":"1441","article-title":"Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death","volume":"27","author":"Qiu","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0070","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0080","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jcb.21426","article-title":"Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection","volume":"103","author":"Caretti","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00109-006-0054-4","article-title":"Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma","volume":"84","author":"Lassus","year":"2006","journal-title":"J Mol Med"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2008.12.003","article-title":"Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash","volume":"113","author":"Schilder","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0105","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1525-1438.2005.00137.x","article-title":"Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study","volume":"15","author":"Gordon","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0120","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0125","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0135","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.23490","article-title":"Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer","volume":"112","author":"Spigel","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0140","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.08.008_bb0145","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810006025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810006025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T21:26:35Z","timestamp":1559683595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810006025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0090825810006025"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.08.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}